Carvedilolum [Latin] en es it fr

Carvedilolum [Latin] Brand names, Carvedilolum [Latin] Analogs

Carvedilolum [Latin] Brand Names Mixture

  • No information avaliable

Carvedilolum [Latin] Chemical_Formula


Carvedilolum [Latin] RX_link

Carvedilolum [Latin] fda sheet

Carvedilolum_[Latin] FDA

Carvedilolum [Latin] msds (material safety sheet)

Carvedilolum_[Latin] MSDS

Carvedilolum [Latin] Synthesis Reference

No information avaliable

Carvedilolum [Latin] Molecular Weight

406.474 g/mol

Carvedilolum [Latin] Melting Point

114-115 oC

Carvedilolum [Latin] H2O Solubility

Practically insoluble (0.583 mg/L)

Carvedilolum [Latin] State


Carvedilolum [Latin] LogP


Carvedilolum [Latin] Dosage Forms


Carvedilolum [Latin] Indication

For the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.

Carvedilolum [Latin] Pharmacology

Carvedilol is a nonselective beta-adrenergic blocking agent with alpha1-blocking activity and is indicated for the treatment of hypertension and mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin. Carvedilol is a racemic mixture in which nonselective b-adrenoreceptor blocking activity is present in the S(-) enantiomer and a-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity. The effect of carvedilol's b-adrenoreceptor blocking activity has been demonstrated in animal and human studies showing that carvedilol (1) reduces cardiac output in normal subjects; (2) reduces exercise-and/or isoproterenol-induced tachycardia and (3) reduces reflex orthostatic tachycardia.

Carvedilolum [Latin] Absorption

Carvedilol is rapidly and extensively absorbed following oral administration, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.

Carvedilolum [Latin] side effects and Toxicity

Not expected to be toxic following ingestion.

Carvedilolum [Latin] Patient Information

Patients taking COREG (Carvedilol) should be advised of the following:

  • they should not interrupt or discontinue using COREG without a physician's advice.
  • congestive heart failure patients should consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath.
  • they may experience a drop in blood pressure when standing, resulting in dizziness and, rarely, fainting. Patients should sit or lie down when these symptoms of lowered blood pressure occur.
  • if patients experience dizziness or fatigue, they should avoid driving or hazardous tasks.
  • they should consult a physician if they experience dizziness or faintness, in case the dosage should be adjusted.
  • they should take COREG with food.
  • diabetic patients should report any changes in blood sugar levels to their physician.
  • contact lens wearers may experience decreased lacrimation.

Carvedilolum [Latin] Organisms Affected

Humans and other mammals